BRPI0203949B8 - polipeptídeo se36, processo para purificação do polipeptídeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético - Google Patents
polipeptídeo se36, processo para purificação do polipeptídeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintéticoInfo
- Publication number
- BRPI0203949B8 BRPI0203949B8 BRPI0203949A BRPI0203949B8 BR PI0203949 B8 BRPI0203949 B8 BR PI0203949B8 BR PI0203949 A BRPI0203949 A BR PI0203949A BR PI0203949 B8 BRPI0203949 B8 BR PI0203949B8
- Authority
- BR
- Brazil
- Prior art keywords
- malaria
- polypeptide
- diagnostic agent
- purification
- dna fragment
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 201000004792 malaria Diseases 0.000 title abstract 4
- 229940039227 diagnostic agent Drugs 0.000 title abstract 3
- 239000000032 diagnostic agent Substances 0.000 title abstract 3
- 229940124735 malaria vaccine Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000003743 erythrocyte Anatomy 0.000 abstract 2
- 244000045947 parasite Species 0.000 abstract 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000224016 Plasmodium Species 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"polipeptídeo se36, processo para purificação do polipeptídeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético". a presente invenção provê um polipeptídeo se36 derivado a partir do domínio n-terminal (47 kd) de sera (antígeno de repetição da serina) produzido pelo parasita da malária, plasmodium falciparium, no estágio eritrocitário; um processo para purificação do mesmo; e uma vacina para malária e um agente de diagnóstico usando como ingrediente ativo o referido antígeno purificado assim obtido. através da deleção de toda a serina polimerizada ou de parte da mesma a partir do domínio de repetição da serina de 47 kd, uma grande quantidade de se36 é produzido pela escherichia coli e pode ser purificado em uma alta extensão. os anticorpos igg3 humanos se ligam especificamente a se36 impedindo extremamente e efetivamente a proliferação do parasita nos eritrócitos e inibe conseqüentemente a febre e a malária cerebral, prevenindo desta forma a morte.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-057458 | 2001-01-24 | ||
| JP2001057458 | 2001-01-24 | ||
| PCT/JP2002/000506 WO2002059319A1 (fr) | 2001-01-24 | 2002-01-24 | Polypeptide se36 de l'antigene malaria plasmodium, procede de purification dudit polypeptide, vaccin et methode diagnostique utilisant l'antigene ainsi obtenu |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0203949A BR0203949A (pt) | 2003-01-28 |
| BRPI0203949B1 BRPI0203949B1 (pt) | 2018-07-03 |
| BRPI0203949B8 true BRPI0203949B8 (pt) | 2021-05-25 |
Family
ID=18917328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0203949-4 BRPI0203949B8 (pt) | 2001-01-24 | 2002-01-24 | polipeptídeo se36, processo para purificação do polipeptídeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20040137512A1 (pt) |
| EP (1) | EP1279735B1 (pt) |
| JP (2) | JP4145145B2 (pt) |
| KR (1) | KR100553646B1 (pt) |
| CN (1) | CN100516219C (pt) |
| AT (1) | ATE442440T1 (pt) |
| AU (1) | AU2002228347C1 (pt) |
| BR (1) | BRPI0203949B8 (pt) |
| CA (1) | CA2404429C (pt) |
| DE (1) | DE60233619D1 (pt) |
| WO (1) | WO2002059319A1 (pt) |
| ZA (1) | ZA200208123B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116261A1 (en) * | 2008-05-07 | 2009-11-11 | Institut Pasteur | Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof |
| BRPI0919245A2 (pt) * | 2008-09-24 | 2021-11-03 | Us Gov Sec Army | Vacina para malária |
| US8293100B2 (en) | 2009-03-13 | 2012-10-23 | Terrasep, Llc | Methods and apparatus for centrifugal liquid chromatography |
| WO2010126151A1 (ja) * | 2009-05-01 | 2010-11-04 | 国立大学法人大阪大学 | 新規マラリアワクチン |
| CN102838659A (zh) * | 2011-06-22 | 2012-12-26 | 中国医学科学院基础医学研究所 | 间日疟原虫抗原的多肽、IgY抗体及其在疟疾诊断上的应用 |
| EP2785370B1 (en) * | 2011-12-02 | 2021-07-21 | Rhode Island Hospital | Vaccine for falciparum malaria |
| CN103965313B (zh) * | 2013-01-28 | 2016-04-13 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN103965327B (zh) * | 2013-01-29 | 2016-08-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN103965324B (zh) * | 2013-01-29 | 2016-08-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN103570817B (zh) * | 2013-11-06 | 2015-07-22 | 中国疾病预防控制中心寄生虫病预防控制所 | 间日疟原虫PvMSP1重组抗原蛋白、其制备方法和用途 |
| JP2017210441A (ja) * | 2016-05-26 | 2017-11-30 | 国立大学法人大阪大学 | マラリアワクチン |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3741057A1 (de) | 1987-03-18 | 1988-09-29 | Behringwerke Ag | Klonierung von malaria-spezifischen dna-sequenzen:isolierung des gens fuer das 140 kd protein |
| US6333406B1 (en) | 1988-08-12 | 2001-12-25 | Joseph W. Inselburg | Gene encoding protein antigens of Plasmodium falciparum and uses therefor |
| WO1990001549A2 (en) * | 1988-08-12 | 1990-02-22 | Trustees Of Dartmouth College | Gene encoding protein antigens of plasmodium falciparum |
| DE4041836A1 (de) | 1990-12-24 | 1992-06-25 | Behringwerke Ag | Protektive plasmodium falciparum hybridproteine, die teilsequenzen der malaria-antigene hrpii und serp enthalten, ihre herstellung und verwendung |
-
2002
- 2002-01-24 WO PCT/JP2002/000506 patent/WO2002059319A1/ja not_active Ceased
- 2002-01-24 CA CA2404429A patent/CA2404429C/en not_active Expired - Lifetime
- 2002-01-24 US US10/239,517 patent/US20040137512A1/en not_active Abandoned
- 2002-01-24 CN CNB028001621A patent/CN100516219C/zh not_active Expired - Lifetime
- 2002-01-24 BR BRPI0203949-4 patent/BRPI0203949B8/pt not_active IP Right Cessation
- 2002-01-24 KR KR1020027012617A patent/KR100553646B1/ko not_active Expired - Lifetime
- 2002-01-24 JP JP2002559804A patent/JP4145145B2/ja not_active Expired - Fee Related
- 2002-01-24 AU AU2002228347A patent/AU2002228347C1/en not_active Expired
- 2002-01-24 EP EP02710343A patent/EP1279735B1/en not_active Expired - Lifetime
- 2002-01-24 AT AT02710343T patent/ATE442440T1/de not_active IP Right Cessation
- 2002-01-24 DE DE60233619T patent/DE60233619D1/de not_active Expired - Lifetime
- 2002-10-09 ZA ZA200208123A patent/ZA200208123B/en unknown
-
2006
- 2006-09-08 US US11/517,455 patent/US7462358B2/en not_active Expired - Lifetime
-
2008
- 2008-03-28 JP JP2008087818A patent/JP4145348B1/ja not_active Expired - Fee Related
- 2008-11-13 US US12/292,206 patent/US7887819B2/en not_active Expired - Fee Related
-
2009
- 2009-07-10 US US12/458,388 patent/US20100016572A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020093000A (ko) | 2002-12-12 |
| HK1058948A1 (zh) | 2004-06-11 |
| BR0203949A (pt) | 2003-01-28 |
| US20100016572A1 (en) | 2010-01-21 |
| US20090104219A1 (en) | 2009-04-23 |
| DE60233619D1 (de) | 2009-10-22 |
| JP4145348B1 (ja) | 2008-09-03 |
| CA2404429C (en) | 2011-02-22 |
| CN100516219C (zh) | 2009-07-22 |
| ZA200208123B (en) | 2003-10-09 |
| US20040137512A1 (en) | 2004-07-15 |
| CN1455815A (zh) | 2003-11-12 |
| EP1279735A4 (en) | 2005-05-25 |
| AU2002228347B2 (en) | 2005-09-15 |
| CA2404429A1 (en) | 2002-08-01 |
| KR100553646B1 (ko) | 2006-02-24 |
| US7887819B2 (en) | 2011-02-15 |
| JPWO2002059319A1 (ja) | 2004-05-27 |
| US20070009994A1 (en) | 2007-01-11 |
| BRPI0203949B1 (pt) | 2018-07-03 |
| US7462358B2 (en) | 2008-12-09 |
| AU2002228347C1 (en) | 2006-05-11 |
| JP2008271958A (ja) | 2008-11-13 |
| ATE442440T1 (de) | 2009-09-15 |
| EP1279735A1 (en) | 2003-01-29 |
| WO2002059319A1 (fr) | 2002-08-01 |
| EP1279735B1 (en) | 2009-09-09 |
| JP4145145B2 (ja) | 2008-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Godal | Immunological aspects of leprosy-present status | |
| Domont et al. | Natural anti-snake venom proteins | |
| CN104230971A (zh) | 作为脂肪酰胺水解酶抑制剂的硼酸和酯 | |
| CY1110700T1 (el) | Ανασυνδυασμενα αντισωματα αντι-cd30 και χρησεις αυτων | |
| BR0203949A (pt) | Polipeptìdeo se36, processo para purificação do polipeptìdeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético | |
| BR0212999A (pt) | novas composições imunogênicas para a prevenção e tratamento de doença meningocócica | |
| JP2005501514A5 (pt) | ||
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| FR12C0001I2 (fr) | Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b | |
| EA199700413A1 (ru) | Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия | |
| BR0213540A (pt) | Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos | |
| MA29678B1 (fr) | Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis | |
| ATE536188T1 (de) | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon | |
| ATE430200T1 (de) | Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus | |
| CA2352765A1 (en) | Hapten-carrier conjugates for treating and preventing nicotine addiction | |
| DE69936977D1 (de) | Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine | |
| BR0207068A (pt) | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus | |
| TW200602071A (en) | Methods for preventing and treating alzheimer's disease (ad) | |
| BR0312456A (pt) | Anticorpo alterado ou fragmento funcional do mesmo, polinucleotìdeo, sequência de polinucleotìdeo, composição farmacêutica, métodos de tratamento ou profilaxia de derrame e outras doenças/distúrbios neurológicos em um ser humano, de inibição da neurodegeneração e/ou promoção da recuperação funcional e de promoção do desenvolvimento axonial, e, uso de um anticorpo anti-mag | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| BR9710089A (pt) | Antìgeno de superfìcie de esperma purificado, anticorpo monoclonal e aplicações para isso | |
| WO2002043660A3 (en) | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment | |
| Smith et al. | Cross‐protection studies with gut membrane glycoprotein antigens from Haemonchus contortus and Teladorsagia circumcincta | |
| BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
| WO2002092131A3 (en) | Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B25A | Requested transfer of rights approved |
Owner name: TOSHIHIRO HORII (JP) , VACCINE BIOTECHNOLOGY CO. ( |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 24/01/2022 |